A simple and validated HPLC method for vancomycin assay in plasma samples: the necessity of TDM center development in Southern Iran

Parisa Ghasemiyeh , Afsaneh Vazin, Farid Zand, Amir Azadi, Iman Karimzadeh, Soliman Mohammadi-Samani


Background and purpose: Vancomycin is a glycopeptide antibiotic which is the drug of choice against methicillin-resistant Staphylococcus aureus. It has a narrow therapeutic index, and thus therapeutic drug monitoring (TDM), and clinical pharmacokinetic assessment are necessary in order to prevent adverse drug reactions such as nephrotoxicity. In this study, we aimed to develop a simple and validated HPLC method for vancomycin assay in order to establish a TDM center for patients admitted to the ICU of Nemazee Hospital in southern Iran.

Experimental approach: In this study, a brief review of different parameters and variables which could affect the sensitivity, selectivity of the validated HPLC method for vancomycin determination were considered. According to the previous studies a simple, fast, and the relatively low-cost method was established for vancomycin determination in plasma samples.

Findings/Results: The developed HPLC assay indicated a calibration curve with R-square of > 0.999, acceptable selectivity, the accuracy of 90-105%, CV% of less than 15%, the limit of quantification of 1 µg/mL, and limit of detection of 300 ng/mL. Vancomycin trough level, the area under the curve, renal clearance, the volume of distribution,, and elimination constant were measured in patients using this validated method.

Conclusion and implications: Validated method for assay of vancomycin plasma levels was used to quantify vancomycin levels of four patients who were admitted to the ICU of Nemazee Hospital. According to the results, two of these patients showed lower levels than recommended therapeutic purposes while one of them showed a toxic level. According to the results, the TDM assessment of vancomycin is strongly recommended for patients who are hospitalized in ICU.




Keywords: Acute kidney injury; AUC; HPLC; ICU; TDM; Vancomycin.

Full Text:



Eirich J, Orth R, Sieber SA. Unraveling the protein targets of vancomycin in living S. aureus and E. faecalis cells. J Am Chem Soc. 2011;133(31):12144-12153.

DOI: 10.1021/ja2039979.

May CC, Erwin BL, Childress M, Cortopassi J, Curtis G, Kilpatrick T, et al. Assessment of acute kidney injury in neurologically and traumatically injured intensive care patients receiving large vancomycin doses. Int J Crit Illn Inj Sci. 2018;8(4):194-200.

DOI: 10.4103/IJCIIS.IJCIIS_39_18.

Vazin A, Japoni A, Shahbazi S, Davarpanah MA. Vancomycin utilization evaluation at hematology-oncology ward of a teaching hospital in Iran. Iran J Pharm Res. 2012;11(1):163-170.

Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42(Suppl 1):S35-S39.

DOI: 10.1086/491712.

Khoei A, Soltani R, Emami J, Badri S, Taheri S. Therapeutic drug monitoring of vancomycin by AUCτ-MIC ratio in patients with chronic kidney disease. Res Pharm Sci. 2019;14(1):84-92.

DOI: 10.4103/1735-5362.251856.

Finch NA, Zasowski EJ, Murray KP, Mynatt RP, Zhao JJ, Yost R, et al. A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity. Antimicrob Agents Chemother. 2017;61(12):e01293,1-10.

DOI: 10.1128/AAC.01293-17.

Zasowski EJ, Murray KP, Trinh TD, Finch NA, Pogue JM, Mynatt RP, et al. Identification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin. Antimicrob Agents Chemother. 2018;62(1):e01684-17,1-9.

DOI: 10.1128/AAC.01684-17.

Usman M, Hempel G. Development and validation of an HPLC method for the determination of vancomycin in human plasma and its comparison with an immunoassay (PETINIA). Springerplus. 2016;5(1):124-130.

DOI: 10.1186/s40064-016-1778-4.

Lima TdM, Seba KS, Gonçalves JCS, Cardoso FLL, Estrela RdCE. A rapid and simple HPLC method for therapeutic monitoring of vancomycin. J Chromatogr Sci. 2017;56(2):115-121.

DOI: 10.1093/chromsci/bmx089.

Hu LQ, Yin CL, Du YH, Zeng ZP. Simultaneous and direct determination of vancomycin and cephalexin in human plasma by using HPLC-DAD coupled with second-order calibration algorithms. J Anal Methods Chem. 2012;2012:256963,1-8.


Hagihara M, Sutherland C, Nicolau DP. Development of HPLC methods for the determination of vancomycin in human plasma, mouse serum and bronchoalveolar lavage fluid. J Chromatogr Sci. 2013;51(3):201-207.

DOI: 10.1093/chromsci/bms128.

Favetta P, Guitton J, Bleyzac N, Dufresne C, Bureau J. New sensitive assay of vancomycin in human plasma using high-performance liquid chromatography and electrochemical detection. J Chromatogr B Biomed Sci Appl. 2001;751(2): 377-382.

DOI: 10.1016/s0378-4347(00)00484-9.

Alasino AB, Caro YS, De Zan MM. Bioanalytical method optimization for the therapeutic drug monitoring of vancomycin. J Anal Bioanal Sep Tech. 2017;2(2):89-95.

DOI: 10.15436/2476-1869.17.1733.

Abu-Shandi KH. Determination of vancomycin in human plasma using high-performance liquid chromatography with fluorescence detection. Anal Bioanal Chem. 2009;395(2):527-532.

DOI: 10.1007/s00216-009-2948-9.

Cao Y, Yu J, Chen Y, Zhang J, Wu X, Zhang Y, et al. Development and validation of a new ultra-performance liquid chromatographic method for vancomycin assay in serum and its application to therapeutic drug monitoring. Ther Drug Monit. 2014;36(2):175-181.

DOI: 10.1097/FTD.0b013e3182a458bc.

Muppidi K, Pumerantz AS, Betageri G, Wang J. Development and validation of a rapid high-performance liquid chromatography method with UV detection for the determination of vancomycin in mouse plasma. J Chromat Separation Techniq. 2013;4(1):1-5.

DOI: 10.4172/2157-7064.1000165.

Plock N, Buerger C, Kloft C. Successful management of discovered pH dependence in vancomycin recovery studies: novel HPLC method for microdialysis and plasma samples. Biomed Chromatogr. 2005;19(3):237-244.

DOI: 10.1002/bmc.446.

Health UDo, Services H. Bioanalytical method validation, guidance for industry. 2001. Available from: http://www.fda.gov/cder/guidance/4252fnl.htm. Accessed January 02, 2019.

Uhrovčík J. Strategy for determination of LOD and LOQ values-some basic aspects. Talanta. 2014;119:178-180.

DOI: 10.1016/j.talanta.2013.10.061.

Tsang M. A Practice of anesthesia for infants and children. Can J Anesth. 2018;65(12):1392-1393.

DOI: 10.1007/s12630-018-1201-4.

Rezazadeh M, Emami J. A simple and sensitive HPLC method for analysis of imipramine in human plasma with UV detection and liquid-liquid extraction: Application in bioequivalence studies. Res Pharm Sci. 2016;11(2):168-176.

Šíma M, Hartinger J, Grus T, Slanař O. Initial dosing of intermittent vancomycin in adults: estimation of dosing interval in relation to dose and renal function. Eur J Hosp Pharm. 2019.

DOI: 10.1136/ejhpharm-2019-002013.

Šíma M, Hartinger J, Netíková IŠ, Slanar O. Creatinine clearance estimations for vancomycin maintenance dose adjustments. Am J Ther. 2018;25(5):e602-e604.

DOI: 10.1097/MJT.0000000000000616.

Soltani R, Khorvash F, Meidani M, Badri S, Alaei S, Taheri S. Vitamin E in the prevention of vancomycin-induced nephrotoxicity. Res Pharm Sci. 2020;15(2):137-143.

DOI: 10.4103/1735-5362.283813.


  • There are currently no refbacks.

Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.